Skip to content

Psilocybin research published in 2024

Page 8 of 19: studies 141 to 160 of 378, newest first. Back to the psilocybin overview

Studies

Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression

Nature Mental Health August 5, 2024 Gustavo Deco, Yonatan Sanz Perl, Samuel Johnson et al. 39 citations

Abstract Effective interventions for neuropsychiatric disorders may work by rebalancing the brain’s functional hierarchical organization. Here we directly investigated the effects of two different serotonergic pharmacological interventions on functional brain hierarchy in major depressive disorder in a two-arm double-blind phase II randomized controlled trial comparing psilocybin therapy (22...

Psilocybin and chronic neuropathic pain: a systematic review

Regional Anesthesia & Pain Medicine August 5, 2024 Harman Chopra, Shravani Durbhakula, Alexander Shustorovich et al. 8 citations

Background/Importance Chronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain management despite being classified as Schedule I. Objective This systematic review critically evaluates the evidence for psilocybin, a Schedule I substance, in the treatment of chronic pain. The exact purpose of the...

DOI: 10.1136/rapm-2024-105532 (opens in new tab) Psilocybin Neuropathic pain Chronic pain Pain management

Overview Of Review (OoR) on PSILOCYBIN in Psychiatric Disorders

August 4, 2024 Pierfelice Cutrufelli, Antonio Di Francesco, Alessandro Rodolico et al.

eview question / Objective This protocol outlines the methodology for an "Overview of Review" (OoR) study which aims to conduct a comprehensive analysis of systematic reviews with meta-analyses of psilocybin randomized clinical trials.The primary objective is to provide an evaluation of the therapeutic effects, safety profiles, and adverse effects of psilocybin as documented in the best...

Predicting the Hallucinogenic Potential of Molecules Using Artificial Intelligence

ACS Chemical Neuroscience August 2, 2024 Fabio Urbina, Thane Jones, Joshua S. Harris et al. 9 citations

The development of new drugs addressing serious mental health and other disorders should avoid the psychedelic experience. Analogs of psychedelic drugs can have clinical utility and are termed “psychoplastogens”. These represent promising candidates for treating opioid use disorder to reduce drug dependence, with rarely reported serious adverse effects. This drug abuse cessation is linked to...

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Annual Review of Psychology August 2, 2024 Keith Humphreys, Daniel Stjepanović, Wayne Hall et al. 18 citations

Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...

Psilocybin-assisted therapy and HIV-related shame

Scientific Reports August 2, 2024 Jennifer Mitchell, Nicky J. Mehtani, Mallory O. Johnson et al. 9 citations

Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic , in part due to limited success...

Precipitous Increases in Psilocybin Exposure in Youths

AAP Grand Rounds August 1, 2024

Research Article| August 01 2024 Precipitous Increases in Psilocybin Exposure in Youths AAP Grand Rounds (2024) 52 (2): 19. https://doi.org/10.1542/gr.52-2-19 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Precipitous Increases in...

Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.

Psychopharmacology August 1, 2024 Kimberly Sakai, Ellen Bradley, Joseph A. Zamaria et al. 10 citations

Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about...

Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Psychopharmacology August 1, 2024 Jacob S. Aday, David Horton, Gisele Fernandes-Osterhold et al. 39 citations

Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been...

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

Journal of Psychiatric Research August 1, 2024 Noah Chisamore, Danica E. Johnson, Margery J.q. Chen et al. 21 citations

Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing preliminary support for its safety and efficacy. However, there is a lack of consistency across existing treatment protocols and psychotherapeutic approaches. The objective of this review is to summarize and compare current psychotherapy methods of PAP in...

Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness.

Current Neurology and Neuroscience Reports August 1, 2024 Daniel C Mograbi, Rafael S. Rodrigues, Bheatrix Bienemann et al. 12 citations

Self-awareness can be defined as the capacity of becoming the object of one's own awareness and, increasingly, it has been the target of scientific inquiry. Self-awareness has important clinical implications, and a better understanding of the neurochemical basis of self-awareness may help clarifying causes and developing interventions for different psychopathological conditions. The current...

Psilocybin desynchronizes the human brain.

Nature August 1, 2024 Joshua S. Siegel, Subha Subramanian, Demetrius Perry et al. 241 citations

A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials1-4. In animal models, psilocybin induces neuroplasticity in cortex and hippocampus5-8. It remains unclear how human brain network changes relate to subjective and lasting effects of psychedelics. Here...

DOI: 10.1038/s41586-024-07624-5 (opens in new tab) Full text (opens in new tab) Psychedelics Brain connectivity Consciousness Mental health

Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors

ACS Chemical Neuroscience August 1, 2024 Samuel C Woodburn, Caleb M. Levitt, Allison M Koester et al. 28 citations

A variety of classic psychedelics and MDMA have been shown to enhance fear extinction in rodent models. This has translational significance because a standard treatment for post-traumatic stress disorder (PTSD) is prolonged exposure therapy. However, few studies have investigated psilocybin's potential effect on fear learning paradigms. More specifically, the extents to which dose, timing of...

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Pharmacological Reports August 1, 2024 Maja Owe-Larsson, Katarzyna Kamińska, Barbara Buchalska et al. 11 citations

Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early...

Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients

Journal of Natural Remedies July 31, 2024 V Suresh, Jitendra Lakhani, R Balaraman

Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good drugs to alleviate the psychiatric...

DOI: 10.18311/jnr/2024/35676 (opens in new tab) Anxiety Psilocybin Antidepressant Depression economics +6

A Comparative Model of Mysticism: Cognitive Neuroscience, Phenomenal Experiences, and Noetic Accounts

Archive for the Psychology of Religion July 26, 2024 Hemal P. Trivedi 2 citations

This article proposes a model of comparative mysticism that bases its rationale for comparison in the dynamic interaction between three components: neurocognitive mechanisms and substrates, phenomenal experiences, and noetic accounts. In examining the phenomenon of ego - dissolution ( EDn ), using this model, a scholar can identify universal and contextual components of a mystic’s experiences....

PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin

Journal of Advances in Medicine and Medical Research July 24, 2024 Ibrahim Lanre Folorunsho, Nkechinyere Mary Harry, Chukwubueze Obiajunwa et al.

Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can occur after experiencing or witnessing a traumatic event. The impact of PTSD extends beyond the individual, affecting families, communities, and society as a whole. This study aims to investigate the potential of psilocybin as a treatment for PTSD. Psilocybin, after being metabolized to psilocin, binds to...

Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants

Psychiatric Research and Clinical Practice July 23, 2024 Chiranth Bhagavan, Richard Kanaan, Olivia Carter et al. 2 citations

Background There has been a resurgence of research into the potential therapeutic benefits of psychedelics for neuropsychiatric disorders. Classic psychedelics, such as psilocybin, exert complex effects on higher cognitive functions such as perception and awareness, but their impact on motor function remains unexplored. Moreover, there is a theoretical rationale for using psychedelics to...

DOI: 10.1176/appi.prcp.20240047 (opens in new tab) Psilocybin Hallucinogen Cognition Subliminal stimuli +3

Wood-loving magic mushrooms from Australia are saprotrophic invaders in the Northern Hemisphere

Fungal Systematics and Evolution July 23, 2024 Alistair R. Mctaggart, K. Scarlettt, Jason C. Slot et al. 5 citations

Magic mushrooms are fungi that produce psilocybin, an entheogen with long-term cultural use and a breakthrough compound for treatment of mental health disorders. Fungal populations separated by geography are candidates for allopatric speciation, yet species connectivity typically persists because there is minimal divergence at functional parts of mating compatibility genes. We studied whether...

DOI: 10.3114/fuse.2024.14.14 (opens in new tab) Ecology Gene flow Evolutionary biology Mutualism biology +1